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Elevated levels of chitinase-3-like-1 (CHI3L1) are associated with poor prognosis, shorter
recurrence-free intervals and low survival in breast cancer patients. Breast cancer
often metastasizes to the lung. We hypothesized that molecules expressed in the
“pre-metastatic” lung microenvironment could support the newly immigrant tumor cells
by providing growth and angiogenic factors. Macrophages are known to play an important
role in tumor growth by releasing pro-angiogenic molecules. Using mouse mammary
tumor models, we have previously shown that during neoplastic progression both the
mammary tumor cells and splenic macrophages from tumor-bearing mice express higher
levels of CHI3L1 compared to normal control mice. However, the role of CHI3L1 in
inducing angiogenesis by macrophages at the pulmonary microenvironment to support
newly arriving breast cancer cells is not yet known. In this study, we determined the
expression of CHI3L1 in bronchoalveolar lavage macrophages and interstitial macrophages
in regulating angiogenesis that could support the growth of newly immigrant mammary
tumor cells into the lung. Here we show that in vitro treatment of pulmonary macrophages
with recombinant murine CHI3L1 resulted in enhanced expression of pro-angiogenic
molecules including CCL2, CXCL2, andMMP-9. We and others have previously shown that
inhibition of CHI3L1 decreases the production of angiogenic molecules. In this study, we
explored if in vivo administration of chitin microparticles has an effect on the expression of
CHI3L1 and pro-angiogenic molecules in the lungs of mammary tumor-bearing mice. We
show that treatment with chitin microparticles decreases the expression of CHI3L1 and
pro-angiogenic molecules in the “metastatic” lung. These studies suggest that targeting
CHI3L1 may serve as a potential therapeutic agent to inhibit angiogenesis and thus
possibly tumor growth and metastasis.
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INTRODUCTION
Metastasis is the major cause of death in breast cancer patients.
It is well established that breast cancer often metastasizes to the
lung. Preferential colonization of specific tissues by breast cancer
cells could be partially determined by the nature of microenvi-
ronment within the target organ (Steeg, 2006). Recent studies
have implicated specific cellular elements in the lungs that con-
tribute to tumor growth. These include airway epithelial cells
and immune cells, such as interstitial and alveolar macrophages,
among others. Studies have demonstrated functional, morpho-
logical, and phenotypic differences between these interstitial and
alveolar macrophages (Sebring and Lehnert, 1992; Prokhorova
et al., 1994; Johansson et al., 1997). However, there are lim-
ited studies on interstitial macrophages in human lungs com-
pared to alveolar macrophages, which can be easily obtained by
bronchoalveolar lavage (BAL). The role of either interstitial or
alveolar macrophages in the pre-metastatic lung in breast can-
cer metastasis has not yet been elucidated. We hypothesize that
interstitial macrophages, alveolar macrophages, or both, may alter
the pre-metastatic landscape of the lung.
Pulmonary macrophages may exert anti-tumor effects to sup-
press the growth of newly-immigrated breast cancer cells, or
alternatively exert pro-tumor effects by producing growth factors
that support their establishment in the lung. By release of pro-
teases, growth factors and cytokines, activated macrophages have
the potential to influence each phase of the angiogenic process.
This includes stimulating remodeling of the local extracellular
matrix, inducing endothelial cells to migrate or proliferate, and
inhibiting formation of differentiated capillaries.
We and others have recently shown that a glycoprotein
known as chitinase-3-like-1 protein is produced by macrophages
from tumor-bearing hosts (Kawada et al., 2012; Libreros et al.,
2012). Chitinase-3-like-1 glycoprotein (aka BRP-39, YKL-40) is
a secreted protein that is upregulated in various types of can-
cers, including breast (Johansen et al., 2003). This molecule is
synthesized under inflammatory conditions, including bronchial
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asthma, inflammatory bowel disease, and cancer, but is not
highly expressed under physiological conditions (Johansen et al.,
2006; Mizoguchi, 2006; Chupp et al., 2007; Coffman, 2008;
Lee et al., 2011; Libreros et al., 2013). CHI3L1 is a chitin-
binding glycoprotein that belongs to the family of chitinase-like
proteins, but is lacking in enzymatic activity (Henrissat and
Bairoch, 1993). This glycoprotein is expressed and secreted by a
variety of cell types including articular chondrocytes, synovio-
cytes, osteoblasts, macrophages, neutrophils, and epithelial cells
(Johansen et al., 2001; Rehli et al., 2003;Mizoguchi, 2006; Rathcke
and Vestergaard, 2006; Lee et al., 2009). In examining the function
of CHI3L1, we and others have found that CHI3L1 stimulates
the production of pro-angiogenic molecules (Shao et al., 2009;
Kawada et al., 2012; Libreros et al., 2012). Conversely, (Shao
et al., 2009) and (Libreros et al., 2012), have shown that inhibit-
ing CHI3L1 with neutralizing antibodies or administration of
chitin microparticles, decreases the expression of pro-angiogenic
molecules (Shao et al., 2009; Libreros et al., 2012).
Currently there is little known regarding mechanistic links
between CHI3L1 expression by macrophages in the “pre-
metatastic” lung, and tumor-related angiogenesis. We therefore
examined the possibility that macrophage-derived CHI3L1 in the
lung, upregulated by exposure to circulating CHI3L1 produced
by tumor cells, “conditions” this organ to favor establishment
of newly-arrived, metastasizing cancer cells. Thus, in this study
we tested the role of CHI3L1 expression by bronchoalveolar
and interstitial macrophages in regulating angiogenesis to pro-
mote the growth of new mammary tumor cells in the lung.
We demonstrate here that: (1) CHI3L1 is secreted by intersti-
tial and alveolar macrophages from mammary tumor bearers;
(2) CHI3L1 induces expression of pro-angiogenic molecules in
interstitial and alveolar macrophages; (3) in vivo treatment with
chitin microparticles reduces angiogenesis; and (4) this treatment
also decreases expression of CHI3L1, CCL2, CXCL2 and MMP-9.
Our findings suggest that CHI3L1 may play a role in prepar-
ing the “soil” in the “pre-metastatic” lung. Therefore, CHI3L1
may be an attractive therapeutic target to inhibit breast cancer
metastasis.
MATERIALS AND METHODS
MICE AND CELL LINES
Female BALB/c mice were used in all studies (Charles River
Laboratories, 8–12 week-olds), and were housed and used accord-
ing to the National Institutes of Health guidelines, under proto-
cols approved by Florida Atlantic University Institutional Animal
Care and Use Committee. Mammary tumor cells (4T1-luc-A4;
Caliper Life Sciences, Hopkinton, MA) were maintained in RPMI
with 10% FCS (Kim et al., 2010). Tumor cells were implanted
in mice by subcutaneous injection of 1 × 1054T1 tumor cells
in the lower right ventral quadrant. These tumors metastasize
to the lung ∼4–5 weeks post-tumor cell implantation. Normal
mice and tumor bearers were assessed at ∼2 weeks- (“pre-
metastatic”) and 5 weeks post-tumor implantation (“metastatic”)
for the expression of cytokines. Tumor bearers treated with chitin
microparticles (see below) were assessed at 5 weeks post-tumor
cell implantation for metastasis, cytokine expression and tumor
angiogenesis using AngioSense probe.
ISOLATION OF EPITHELIAL CELLS AND MACROPHAGES FROM THE
LUNGS
Bronchoalveolar macrophage isolation
Tracheas of euthanized mice were cannulated and lavaged with
1mL of saline. The bronchoalveolar lavage fluid (BALF) was
recovered to obtain alveolar macrophages as described by Kogiso
et al. (2011). Plastic-adherent macrophages were then enriched
by incubating BALF cells (106 cells/mL) in complete media
(RPMI 1640 with 10% FBS, 10 units/mL penicillin and 10μg/mL
streptomycin) for 1 h in a 5% CO2 incubator at 37◦C. Non-
adherent cells were removed by washing with media, and
the BALF macrophages were then isolated by labeling with
CD11b magnetic microbeads (Miltenyi Biotec, Cambridge, MA).
CD11b+ cells were purified by positive selection using AutoMACs
(Miltenyi). Alveolar CD11b+macrophages isolated from all ani-
mals revealed >90% purity as determined by flow cytometric
analysis (FACS Calibur).
Isolation of alveolar epithelial cells and interstitial macrophages
Immediately after collecting BALF specimens, pulmonary epithe-
lial cells and interstitial macrophages were isolated as previously
described, with modifications [35]. Media (1mL, RPMI 1640
with 2% FBS and 1mg/mL dispase (Invitrogen, Grand Island,
NY)) was perfused into the airways and alveoli of the lungs. The
lungs were then removed and incubated at 37◦C for 1 h in the
samemedia with 2mg/mL collagenase type II (Invitrogen) added,
followed by tissue mincing. Cells were filtered through Teflon
mesh of 40μM pores and washed with the media with no cen-
trifugation at 0◦C. Macrophages were isolated by plastic adher-
ence, and were then purified by magnetic beads as described. The
purity of the cells was>90% for CD11b expression as determined
by flow cytometric analysis. Non-adherent cells (alveolar epithe-
lial cells) were labeled with CD146 microbeads (MiltenyiBiotec)
and purified by AutoMACs (MiltenyiBiotec). The purity was
confirmed to be>90% as assessed by flow cytometric analysis.
Cell culture
Purified alveolar epithelial cells, and alveolar and interstitial
macrophages, were cultured at 2 × 106 cells/mL for 18 h in com-
plete media as described previously (Owen et al., 2005). All cells
were stimulated with either 500 ng/mL LPS (Sigma Chemical Co.,
St. Louis, MO), or in combination with 1 ng/mL or 5 ng/mL
of endotoxin-free rmCHI3L1 (R&D systems, Minneapolis, MN).
Growthmedia (GM)was included as a control condition for some
of the cultures. Cell-free supernatants were then collected and
stored at −80◦C.
FLOW CYTOMETRY
Total lung homogenates and BALF cells were isolated and resus-
pended in FACS buffer (PBS with 1% BSA and 0.1% sodium
azide) and stained for 30min at 4◦C with FITC-conjugated
antibodies against CD11b (BDBiosciences, San Jose, CA), APC-
conjugated Ly6C, PerCP-conjugated Ly6G, PerCPF4/80 (all from
BDBiosciences) or CD146 (Miltenyi Biotec). Isotype-matched
IgG was used for internal controls. For intracellular cytokine
staining, BD cytofix/cytoperm + fixation/permeabilization kit
were used according to manufacturer’s instructions and this was
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followed by labeling for CHI3L1. CHI3L1 antibody (generously
provided by Dr. Alison Humbles, MedImmune, MD) was conju-
gated to a fluorescent dye using Lightning-Link PE conjugation
kit (Novus, Littleton, CO) following manufacturer’s instructions.
Samples were acquired in a FACSCalibur flow cytometer (BD
Biosciences) and analyzed by Flow Jo software (Tree Star, Inc.,
Ashland, OR).
CYTOKINE ELISA
BALF samples and culture supernatants from cells obtained from
control and mammary tumor bearers were analyzed for CHI3L1,
CCL2, CXCL2 and MMP-9 levels by ELISA (all from R&D
Systems) according to manufacturer’s instructions. Absorbance at
450 nm with wavelength correction at 570 nm was measured with
a Tecan SLT Rainbow Reader (Lab Instruments, Research Triangle
Park, NC) and optical density (OD) values of samples were con-
verted to picograms against a standard curve plotted from known
quantities of recombinant murine cytokines.
WESTERN BLOT ANALYSIS
Cells from total lung homogenates were lysed with sample buffer
(20mM dithiothreitol, 6% SDS, 0.25M Tris, pH 6.8, 10% glyc-
erol, 10mM NaF and bromophenyl blue) and used to extract
total protein. Total protein (20μg) was resolved on 4–20% Mini-
Protean SDS-PAGE gradient gels (BioRad Life Sciences, Hercules,
CA) and transferred to PVDF membrane (Pierce) using a semi-
dry transfer transblotter (BioRad). The membranes were blocked
overnight at 4◦C in SeaBlock (Calbiochem), and subsequently
incubated at room temperature for 1 h with anti-mouse CHI3L1
polyclonal antibody (1μg/mL) (Quidel, San Diego, CA) and
anti-mouse beta actin polyclonal antibody (0.25μg/mL) (Li-Cor
Biosciences, Lincoln, NE). Immunoblots were washed with 0.5%
Tween-PBS followed by 1 h incubation at room temperature with
appropriate infrared dye-conjugated secondary antibodies (Li-
Cor Biosciences). Blots were washed again with 0.5% Tween-PBS
and then dried at 37◦C for 20min. The membranes then were
imaged and bands quantified using the Li-Cor Odyssey imag-
ing system. Levels of proteins of interest were normalized to
beta-actin.
CONFOCAL MICROSCOPY
Lungs from control mice and 2-week mammary tumor bear-
ers were perfused with a mixture of Optimal Tissue Cutting
(OCT) embedding compound and PBS (70%/30% respectively).
The lungs were then removed and snap frozen on dry ice.
5μM cryostat sections were mounted on SuperFrost Plus slides
(Fisher Scientific, Fair Lawn, NJ), fixed in 4% paraformalde-
hyde, and labeled with goat anti-mouse CC10 (1:100, Santa
Cruz Biotech, Santa Cruz, CA) and rabbit anti-mouse CHI3L1
(1μg/μL, Quidel) as described below. Alveolar and interstitial
macrophages were plated (0.5 x 106 cells) on coverslips, fixed in
4% paraformaldehyde, and labeled with goat anti-mouse CD68
(1:100, macrophage marker) (Santa Cruz Biotech) and rabbit
anti-mouse CHI3L1 (Quidel). Both cryostat sections and cells
were blocked in 10% normal horse serum in PBS prior to
staining with primary antibodies overnight at 4◦C. After wash-
ing in PBS, cells and sections were incubated in the following
secondary antibodies: FITC-donkey anti-rabbit and PE-donkey
anti-goat (1:2000, both from Invitrogen, Life Technologies). To
visualize nuclei, material was mounted with Vectashield contain-
ing DAPI (Vector Laboratories, Burlingame, CA), and examined
by confocal microscopy (Carl Zeiss LSM 700, Microimaging,
Thornwood, NY).
In vivo TREATMENT WITH CHITIN MICROPARTICLES
Chitin microparticles (1–10μM, kindly provided by Dr. Yoshimi
Shibata, Florida Atlantic University, FL) were prepared as
described previously (Shibata et al., 1997; Strong et al., 2002;
Nishiyama et al., 2006). Tumor-bearing mice were treated by
intraperitoneal injection with chitinmicroparticles (1mg/mouse)
starting 3 days post-tumor implantation and continuing every
third day for 5 weeks (Libreros et al., 2012).
ANGIOGENESIS DETERMINATION
To assess vascularization in vivo, the near-infrared blood pool
agent AngioSense 680 probe (2 nmol/mouse in 150μL volume;
Perkin Elmer, Waltham, MA) was injected via tail vein 24 h before
imaging. Mice were imaged using a bioluminescence optical
imager (IVIS Lumina LTE, Perkin Elmer). Maximal near infrared
signals were quantified using Living Image 2.5 image analysis soft-
ware (Xenogen, Perkin Elmer). Infrared signals are reported as
photons/sec.
STATISTICAL ANALYSES
Results are expressed as group means ± SD. Statistical analy-
ses were performed using GraphPad Prism 3 software (LaJolla,
CA). Statistical comparisons of paired groups were determined by
Student’s t tests. Values of p < 0.05 were considered statistically
significant.
RESULTS
CHI3L1 EXPRESSION IS INCREASED IN BALF AND TOTAL LUNG FROM
MAMMARY TUMOR-BEARING MICE
Increased levels of CHI3L1 in the sera of breast cancer patients
are associated with poor prognosis (Johansen et al., 2003). We
have previously reported higher circulating levels of CHI3L1 in
4T1 mammary tumor-bearing mice compared with normal mice
(Libreros et al., 2012). This tumor model shares similar char-
acteristics with human breast cancer patients as mice bearing
4T1 mammary tumors exhibit spontaneous tumor cell metasta-
sis to the lung. The levels of CHI3L1 in the lungs are increased
during pulmonary inflammation, and inflammation is known to
contribute to tumor growth and metastasis. Since it is known
that breast tumor cells metastasize to the lung, we determined if
CHI3L1 expression is specifically altered in lungs of mammary
tumor bearers compared to control mice.
The “pre-metastatic” and “metastatic” stages were described
by Yan et al. using the 4T1 mammary tumor model, with
the pre-metastatic stage occurring at 14 days post-tumor cell
inoculation, and the metastatic stage at 4 weeks (Yan et al.,
2010). We therefore assessed CHI3L1 expression in the lungs
of mice inoculated with 4T1 mammary tumor cells at 2 weeks
post-cell implantation, a time point at which no visible micro-
metastasis is observed in the lungs (data not shown), and at
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5 weeks when metastasis of 4T1 cells is known to be well-
established (Yan et al., 2010; Libreros et al., 2012). We first
measured circulating levels of CHI3L1, which increased from
25 × 103 ng/mL at 2 weeks, to 125 × 103 ng/mL at 5 weeks
(Figure 1A). ELISA measurements demonstrated that signifi-
cantly higher levels of CHI3L1 were also present in both BALF
samples (Figure 1B) and total lung homogenates (Figure 1C) at
5 weeks post-tumor cell implantation, compared to the 2-week
time point. These higher levels of CHI3L1 could be due to
expression by the pulmonary tissue itself and/or the tumor
cells that have infiltrated by 5 weeks (Libreros et al., 2013).
Samples from the “pre-metastatic” stage would help differentiate
between these possibilities, as tumor cells have not yet infil-
trated, and we performed additional analyses at this stage. At
2 weeks post-inoculation, significantly higher levels of CHI3L1
were measured by ELISA in BALF samples from tumor bear-
ers compared to control mice (Figure 2A). Western blot analysis
of whole lungs from pre-metastatic tumor-bearers confirmed
higher levels of pulmonary CHI3L1 (Figure 2B), and ELISA
assays of total lung homogenates quantified this increase at 2
weeks (Figure 2C). CHI3L1 is secreted by a variety of cell types,
including macrophages, neutrophils, colonic epithelial cells, and
chondrocytes (Nyirkos and Golds, 1990; Hakala et al., 1993;
Renkema et al., 1998; Volck et al., 1998; Mizoguchi, 2006), and
recent studies by Lee et al. (2009) have shown that CHI3L1 (aka
BRP-39) is upregulated in inflamed airway epithelium, and that
it plays an active role in pulmonary inflammation (Lee et al.,
2009). We therefore determined if CHI3L1 expression is specifi-
cally altered in lung epithelial cells isolated frommammary tumor
bearers at 2 weeks post-inoculation, compared to those from
control mice. Production of CHI3L1 was increased more than
5-fold in pulmonary epithelial cells from tumor bearers, as mea-
sured by ELISA at 18 h post-plating (Figure 2D). To promote
“inflammatory” conditions, cultures were treated with LPS to
stimulate cytokine production, which exacerbated the increase in
CHI3L1 levels displayed by cells from tumor bearers (Figure 2D).
Localization of CHI3L1 in lung tissue samples by immunofluo-
rescence showed that CHI3L1 was expressed by lung epithelial
cells (CC10+ cells), and that this expression was increased in the
airways of mammary tumor bearing mice compared to controls
(Figure 2E).
CHI3L1 EXPRESSION IS INCREASED IN CD11B+GR1+ CELLS OF
MAMMARY TUMOR BEARERS
Myeloid-derived cells have been shown to be important in
promoting tumor growth, metastasis, and angiogenesis (van
Kempen and Coussens, 2002; Yang et al., 2004). The lungs of
4T1 mammary tumor bearers show infiltration by myeloid-
derived suppressor cells, and in particular by CD11b+Gr1+ cells
that establish a pre-metastatic niche by secreting proinflam-
matory mediators (Yan et al., 2010; Younos et al., 2011). We
have previously shown that splenic myeloid cells from mam-
mary tumor-bearing mice express CHI3L1 (Libreros et al., 2012).
To clearly delineate myeloid populations of cells in pulmonary
tissue that could contribute to CHI3L1 expression, single cell
suspensions prepared from total lungs of normal and 2-week
mammary tumor-bearers were analyzed by flow cytometry. As
FIGURE 1 | CHI3L1 is expressed in serum and pulmonary tissue of
mammary tumor-bearing mice at 2 weeks (“pre-metastatic”) and 5
weeks (metastatic) post-tumor cell implantation. (A) Serum (B) BALF
and (C) Total lung homogenates from 2 week and 5 week mammary tumor
bearers were analyzed for CHI3L1 expression by ELISA. N = 10
mice/group; ∗∗p ≤ 0.001.
shown in Figures 3A–C (one representative assay out of five),
CD11b+Ly6C+ cells from mammary tumor bearers express
CHI3L1 at higher levels compared to normals. CD11b+Ly6G+
cells from tumor bearers express CHI3L1 but these levels are
lower compared to the levels observed in CD11b+Ly6C+ cells
(Figures 3D–F).
Since BALF was shown to contain elevated levels of CHI3L1,
we determined which cell populations in the lavage contribute
to the expression of CHI3L1 at 2 weeks post-tumor cell inocula-
tion. Toward this we assessed CD11b+Ly6C+ and CD11b+Ly6G+
cells in the lavage. CD11b+Ly6C+ cells from mammary tumor
bearers express higher levels of CHI3L1 compared to normals
(Figures 4A–C). Similar to what was observed in total lung
homogenates, CD11b+Ly6G+ cells from tumor bearers express
CHI3L1 at lower levels compared to the CD11b+Ly6C+ cells
(Figures 4D–F).
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FIGURE 2 | CHI3L1 is expressed at higher levels in the pulmonary tissue
of 2-week 4T1 mammary tumor bearers. (A) CHI3L1 expression in
bronchoalveolar lavage fluid by ELISA; (B) Western blot analysis of total lung
homogenates for CHI3L1 expression; (C,D) CHI3L1 expression by ELISA of
total lung homogenates (C) and lung epithelial cells (D). (E) Cellular
co-localization of CHI3L1 with CC10, an airway-epithelial cell marker, in
cryostat sections visualized by confocal microscopy. For all experiments,
N = 10/group; ∗p ≤ 0.05; ∗∗p ≤ 0.001.
CHI3L1 EXPRESSION IS INCREASED IN MACROPHAGES FROM THE
LUNGS OF MAMMARY TUMOR-BEARING MICE
We have previously shown that CHI3L1 is expressed at higher
levels in splenic macrophages of mammary tumor-bearing mice
(Libreros et al., 2012). In this study, we determined the expres-
sion levels of CHI3L1 in macrophages from the “pre-metastatic”
lungs. Two broad subsets of macrophages are found in the
lungs of mice and humans, i.e., alveolar macrophages which
line the surface of alveoli, and interstitial macrophages that are
localized in the space between alveolar epithelium and vascular
endothelium (Schneberger et al., 2011). Thus, alveolar and inter-
stitial macrophages from normal and 2-week tumor bearers were
purified as described in the Methods section, and cultured in
either the absence or presence of LPS. Interstitial macrophages
from mammary tumor-bearing mice secrete CHI3L1 and these
levels were further increased by stimulation with LPS as deter-
mined by ELISA (Figure 5A). Localization of CHI3L1 in inter-
stitial macrophages was then confirmed by immunofluorescent
labeling. Confocal images revealed higher intensity of CHI3L1
expression in CD68+interstitial macrophages from tumor bear-
ers, relative to normal mice (Figure 5B). Purified alveolar
macrophages were also analyzed. Similar to what was observed
in the interstitial macrophage population, there were higher than
normal levels of CHI3L1 present in culture supernatants of alve-
olar macrophages from 2 week tumor-bearing mice (Figure 5C).
Intensity of CHI3L1 staining in alveolar macrophages similarly
was greater in tumor bearers’ macrophages, as determined by
confocal microscopy (Figure 5D). Interestingly, the expression
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FIGURE 3 | CHI3L1 is expressed at higher levels in CD11b+Ly6C+ total
lung cells in 2-week mammary tumor bearers. (A,D) Representative
scatter plots of forward scatter vs. side scatter in total lung from normal and
tumor bearers; (B) CD11b+Ly6C+ cells from total lungs of normal and tumor
bearers and assessed for CHI3L1 expression; (C) Representative overlay
histogram plot gated on CD11b+ and Ly6C+ cells for CHI3L1 expression; (E)
CD11b+Ly6G+ cells from total lungs of normal and tumor bearers and
assessed for CHI3L1 expression; (F) Representative overlay histogram plot
gated on CD11b+ and Ly6G+ cells for CHI3L1 expression. For all
experiments, N = 10/group; ∗p ≤ 0.05; ∗∗p ≤ 0.001.
levels of CHI3L1 were higher in interstitial macrophages com-
pared to alveolar macrophages.
CHI3L1 EXACERBATES THE PRODUCTION OF PRO-ANGIOGENIC
MOLECULES IN LPS-STIMULATED PULMONARY MACROPHAGES
Yan et al. (2010) found that the expression of MMP-9 and CCL-2
is upregulated in the lungs of 2 week tumor-bearing mice com-
pared to normal mice (Yan et al., 2010). We and others have
shown that CHI3L1 induces the expression of CCL2, CXCL2
and MMP-9 in splenic macrophages (Mizoguchi, 2006; Letuve
et al., 2008; Kawada et al., 2012; Libreros et al., 2012), but there
are few studies to date on the biological role of CHI3L1 in
pulmonary macrophages. In this study we tested the effects of
CHI3L1 on interstitial and alveolar macrophages isolated from
normal mice, and analyzed the production of the pro-angiogenic
molecules CCL2, CXCL2 and MMP-9 by ELISA. Cells were
treated with CHI3L1 in combination with LPS, which is necessary
for expression of angiogenic molecules by ex vivo macrophages.
Treatment of either interstitial or alveolar macrophages with
LPS alone or in combination with rmCHI3L1 (1 ng/mL or
5 ng/mL) resulted in a dose-dependent increase in the production
of CCL2 (Figures 6A,B), CXCL2 (Figures 6C,D) and MMP-9
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FIGURE 4 | CHI3L1 is expressed at higher levels in CD11b+Ly6C+
bronchoalveolar lavage cells in 2-week mammary tumor bearers. (A,D)
Representative scatter plots of forward scatter vs. side scatter in alveolar
lavage from normal and tumor bearers; (B) CD11b+Ly6C+ cells from alveolar
lavage of normal and tumor bearers and assessed for CHI3L1 expression; (C)
Representative overlay histogram plot gated on CD11b+ Ly6C+ cells for
CHI3L1 expression; (E) CD11b+Ly6G+ cells from alveolar lavage of normal
and tumor bearers and assessed for CHI3L1 expression; (F) Representative
overlay histogram plot gated on CD11b+Ly6G+ cells for CHI3L1 expression.
For all experiments, N = 10/group; ∗p ≤ 0.05; ∗∗p ≤ 0.001.
(Figures 6E,F) in both interstitial and alveolar macrophages.
Culturing with rmCHI3L1 alone in the absence of LPS revealed
a similar trend to the one observed in cultures containing both
LPS and rmCHI3L1, but the levels of the proinflammatory medi-
ators secreted were lower (data not shown). The combined effects
of LPS and rmCHI3L1 produced the greatest increase in the
expression of pro-angiogenic molecules.
In vivo TREATMENT WITH CHITIN MICROPARTICLES DECREASES
ANGIOGENESIS
Intraperitoneal treatment of mammary tumor bearers with chitin
microparticles, a substrate for CHI3L1, results in decreased
tumor growth and pulmonary metastasis (Libreros et al., 2012).
We and others established that 4T1 mammary tumors begin
to infiltrate the lungs by 3 weeks post-tumor cell implanta-
tion, and observable metastatic foci are seen in the lungs at 5
weeks post-tumor cell implantation (Yan et al., 2010; Libreros
et al., 2012). Therefore, we used 5 week tumor bearers to assess
the effects of in vivo chitin microparticle treatment. To test
if early treatment with chitin microparticles affects angiogene-
sis and tumor growth, an in vivo AngioSense probe was used.
Mice treated with chitin microparticles after tumor cell inocula-
tion had significantly reduced angiogenic fluorescent signals in
in vivo imaged tumors compared to the tumors from untreated
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FIGURE 5 | CHI3L1 is expressed at higher levels in pulmonary
macrophages from 2-week mammary tumor bearing mice. (A)
CHI3L1 ELISA of interstitial macrophages from normal and
mammary tumor bearers; (B) Cellular co-localization of CHI3L1
with CD68, a macrophage marker was visualized by confocal
microscopy, scale bar 10μM; (C) CHI3L1 ELISA of alveolar
macrophages from normal and mammary tumor bearers; (D)
Cellular localization of CHI3L1 was visualized by confocal
microscopy, scale bar 10μM. For all experiments, N = 10/group;
∗p ≤ 0.05; ∗∗p < 0.001.
FIGURE 6 | CHI3L1 increases the expression of CCL2, CXCL2 and
MMP-9. Pulmonary macrophages from normal mice were cultured
overnight with LPS (500 ng/mL) alone and with either 1 ng/mL or
5 ng/mL of rmCHI3L1. Cell free supernatants were then analyzed for
CCL2 in: (A) interstitial or (B) alveolar macrophages; CXCL2 in: (C)
interstitial or (D) alveolar macrophages; and MMP-9 in: (E) interstitial
or (F) alveolar macrophages. For all experiments, N = 10/group;
∗p ≤ 0.05; ∗∗p ≤ 0.001.
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mice (Figure 7A). Quantification of fluorescent signals confirmed
these results (Figure 7B). Previously we noted that tumor size
in chitin-treated, 5 week tumor-bearing mice was significantly
smaller than normal. We now show with the AngioSense probe
that there was a significant decrease in angiogenic fluorescent sig-
nals in the excised tumors of chitin-treated mice, compared to
untreated tumor bearers (Figure 7C). Quantification of fluores-
cent signals is depicted in Figure 7D.
Following metastasis, decreased tumor growth in the target
organ also could be due to decreased angiogenesis. Since treat-
ment with chitin microparticles decreased angiogenesis in the
primary tumor, we tested to see if in vivo treatment with chitin
microparticles also had an effect on angiogenesis in the metastatic
lung. Excised lungs from chitin-treated and untreated mice at 5
weeks post-tumor cell inoculation were imaged as above to eval-
uate angiogenesis. Similar to what was observed in the tumor
tissue, there was a significant reduction in fluorescent AngioSense
signals, indicating decreased angiogenesis in the lungs of mice
treated with chitin microparticles, compared to untreated con-
trols (Figure 7E). Quantification of these fluorescent signals is
shown in Figure 7F.
In vivo TREATMENT WITH CHITIN MICROPARTICLES DECREASES THE
PRODUCTION OF PRO-ANGIOGENIC MOLECULES BY PULMONARY
MACROPHAGES
Faibish et al. (2011) found that neutralizing antibody to YKL-40
blocks tumor angiogenesis by inhibiting endothelial cell tube for-
mation (Faibish et al., 2011) while (Kawada et al., 2012) demon-
strated increased microvessel density in CHI3L1-transfected
colon cancer cells (Kawada et al., 2012). Since CHI3L1 expression
by splenic macrophages is altered in vivo by chitin microparticle
treatment (Libreros et al., 2012) we next determined if CHI3L1
expression in lung tissue is similarly affected. Bronchoalveolar
lavage fluid was analyzed for the expression of pro-angiogenic
FIGURE 7 | In vivo treatment with chitin microparticles decreases
angiogenesis. 4T1 mammary tumor bearers at 5 weeks post-tumor
implantation were treated in vivo with chitin microparticles (1mg/mL) and
analyzed for angiogenesis using AngioSense probe by in vivo imaging
system. (A) Ventral image of untreated and chitin treated mammary tumor
bearing mice showing 2 out 5 mice/treatment group; (B) Quantification
(photons/s) of AngioSense specific fluorescent signal indicating decreased
angiogenesis at 21 days post-tumor implantation in the chitin treated
group; (C) Excised tumors from untreated and chitin treated mice
indicating decreased fluorescent signal in the chitin treated group; (D)
Quantification (photons/s) of AngioSense specific fluorescent signal
indicating decreased angiogenesis at 21 days post-tumor implantation in
the chitin treated group; (E) Excised lungs from untreated and chitin
treated mice indicating decreased fluorescent signal in the chitin treated
group; (F) Quantification (photons/s) of AngioSense specific fluorescent
signal indicating decreased angiogenesis in the lungs at 21 days
post-tumor implantation in the chitin treated group compared to untreated
group. For all experiments, N = 5/group; ∗∗p ≤ 0.001.
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molecules. In vivo treatment with chitin microparticles resulted
in decreased CHI3L1 expression in BALF collected form 5 week
tumor-bearers (Figure 8A). As CHI3L1 promotes expression of
pro-angiogenic molecules, we reasoned that decreased CHI3L1
levels in chitin-treated mice should result in decreased expres-
sion of pro-angiogenic molecules. We found that the levels of
CCL2 (Figure 8B), CXCL2 (Figure 8C) and MMP-9 (Figure 8D)
in BALF samples were indeed decreased by in vivo chitin treat-
ment. We also found that interstitial and alveloar macrophages
from chitin-treated mammary tumor bearers exhibited reduced
expression of CHI3L1, and these same pro-angiogenic molecules,
at 5 weeks post-tumor cell inoculation (Figure 9).
DISCUSSION
Circulating tumor cells must invade and proliferate in a target
organ to establish metastasis. It is well established that preferen-
tial tissue colonization is determined not only by features intrinsic
to the type of tumor cell, but also in part by the unique nature of
each target organ (Steeg, 2006). Themicroenvironment, the “soil”
or the “pre-metastatic niche,” in the target organ contributes to
the survival of these cells. To our knowledge, there are no studies
to date defining the role of CHI3L1 in pulmonary tissue in terms
of promoting survival and growth of invading breast cancer cells.
In this study, we examined the role of pulmonary macrophages
in preparing the “soil” or the “pre-metastatic niche” for establish-
ing breast cancer metastasis. We used an in vivomouse mammary
tumor model mimicking CHI3L1 expression in breast cancer
patients to examine the role of CHI3L1 and CHI3L1-induced
angiogenic molecules in the pulmonary microenvironment dur-
ing the emergence of metastasis.
We show here that CHI3L1 levels are increased in both the
“pre-metastatic” lung and “metastatic” lung of mammary tumor-
bearing mice. Higher levels of CHI3L1 were observed not only
in the serum, but also in BALF and lung tissue homogenates.
We found that expression of CHI3L1 is upregulated in lung
epithelial cells, as well as in alveolar and interstitial macrophages
of mammary tumor-bearing mice. Importantly, CHI3L1 was
FIGURE 8 | In vivo treatment with chitin microparticles decreases
CHI3L1, CCL2, CXCL2, and MMP-9 expression in BALF. BALF from
untreated and chitin treated mice at 5 weeks post-tumor implantation was
analyzed for: (A) CHI3L1; (B) CCL2; (C) CXCL2; and (D) MMP-9 expression
by ELISA. For all experiments, N = 10/group; ∗∗p ≤ 0.001.
found to induce the production of angiogenic molecules, CCL2,
CXCL2 and MMP-9 in both alveolar and interstitial macrophages
from normal mice. We also demonstrate that in vivo treatment
with chitin microparticles, a substrate for CHI3L1, resulted in
decreased production of CHI3L1, CCL2, CXCL2, and MMP-
9 in BALF, and more specifically by interstitial and alveolar
macrophages of mammary tumor-bearing mice. Decreased pro-
duction of these molecules has been correlated with decreased
levels of angiogenesis in tumors (Arenberg et al., 1998; Mehrad
et al., 2007; Gerber et al., 2009). Transfection of HCT116
tumor cells with CHI3L1 enhances tumor growth, while in vivo
treatment with anti-CHI3L1 neutralizing antibodies decreases
angiogenesis (Shao et al., 2009; Kawada et al., 2012). Using
administration of chitin microparticles, a molecule that binds
to chitinases and chitin-like molecules (Ober and Chupp, 2009),
we have shown previously that splenic macrophages from treated
mice produce lower levels of pro-angiogenic molecules compared
to untreated mammary tumor bearers, and that tumor growth
and metastasis are reduced by this treatment (Libreros et al.,
2012). To monitor angiogenesis during the “metastatic” stage,
FIGURE 9 | In vivo treatment with chitin microparticles decreases
CHI3L1, CCL2, CXCL2, and MMP-9 expression in pulmonary
macrophages from 5 week mammary tumor bearers. Interstitial
macrophages from untreated and chitin treated mice was analyzed for:
(A) CHI3L1; (B) CCL2; (C) CXCL2; and (D) MMP-9 expression by ELISA,
and alveolar macrophages from untreated and chitin treated mice was
analyzed for: (E) CHI3L1; (F) CCL2; (G) CXCL2; and (H) MMP-9 expression
by ELISA. For all experiments, N = 10/group; ∗p ≤ 0.05; ∗∗p ≤ 0.001.
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in this study we used the AngioSense 680 probe, a marker for
blood vessel density, to directly assess in vivo tumor angiogen-
esis. In vivo imaging clearly demonstrated the effectiveness of
chitin microparticle treatment on angiogenesis. Chitin-treated
mice had lower fluorescent signals compared to the untreated
controls, and more importantly, excised tumors, as well as lungs
from treated mice, had lower levels of AngioSense signals com-
pared to the untreated group. It is well-established that tumors
do not grow >1mm3 in size without an adequate blood supply
(Folkman, 1971), and our results indicate that decreased angio-
genesis in mammary tumors correlates well with the smaller size
of these tumors in chitin-treated mice. In this study, tumor size
as determined by assessing for luciferase signals revealed <0.5 ×
106 photons in treated group vs. 3 × 106 in untreated group (p <
0.005). Reduced angiogenesis in the lungs also correlates well with
the lower levels of pro-angiogenic molecules expressed by alveolar
and interstitial macrophages in the chitin-treated group.
Macrophages have been described to be one of the key play-
ers in many types of cancers by producing a variety of factors
that can either promote or inhibit tumor growth and metasta-
sis (Mantovani et al., 2002). Numerous studies have reported on
the role of tumor-infiltrating macrophages (TAMs) on tumor
growth. There are very few reports on the role of macrophages
at a metastatic site in terms of supporting the growth of infil-
trating tumor cells. As the metastatic site offers new challenges
for circulating tumor cells in terms of their survival, our focus
has been to characterize macrophages in the lung microenvi-
ronment of mammary tumor bearers in terms of how they may
support invading breast cancer cells. Although tumor cells and
activated splenic macrophages express CHI3L1, a molecule asso-
ciated with poor prognosis in breast cancer patients (Lal et al.,
1999; Lau et al., 2006; Coffman, 2008; Libreros et al., 2012),
few studies have analyzed CHI3L1 expression by alveolar and
interstitial macrophages in tumor bearing models. In compar-
ing the different cell types present in the lung, i.e., epithelial cells
and macrophages, we found that both interstitial and alveolar
macrophages from 2 weekmammary tumor-bearingmice express
much higher levels of CHI3L1 compared to epithelial cells. Prior
work by Chupp et al., reported higher levels of CHI3L1 expression
in biopsied lung tissue from patients with severe asthma, com-
pared to those with a milder form, and that it localizes to the
subepithelium of pulmonary tissue (Chupp et al., 2007). Using
ova-sensitized and challenged mice, Lee et al. (2009) showed
that CHI3L1 is expressed by airway epithelial cells and F4/80-
positive macrophages during antigen-induced inflammation (Lee
et al., 2009). Our results suggest that at early, pre-metastatic
stages, CHI3L1 expression by either the airway epithelium or
by “activated” lung macrophages may be induced by circulat-
ing tumor-derived factors including CHI3L1, and that this in
turn promotes conditions that favor the later establishment of
infiltrating tumor cells.
The biological roles of CHI3L1 have been recently character-
ized in terms of cell proliferation, angiogenesis, chemotaxis, and
cell adhesion (Coffman, 2008; Shao et al., 2009; Kawada et al.,
2012). We have previously shown that splenic macrophages from
mammary tumor-bearing mice secrete higher levels of the pro-
angiogenic molecules CCL2, CXCL2, and MMP-9 (compared to
non-tumor bearers) and that CHI3L1 stimulates this increased
production (Libreros et al., 2012). There are only few studies to
date that have compared the production of angiogenic molecules
by alveolar and interstitial macrophages in response to CHI3L1 in
the context of inflammation. Letuve et al., showed that smokers
with chronic obstructive pulmonary disease (COPD) had ele-
vated serum levels of CHI3L1, and BALF samples contained a
greater proportion of alveolar macrophages expressing CHI3L1
than smokers without COPD or non-smokers (Letuve et al.,
2008). Inflammation associated with pulmonary sarcoid granulo-
mas is also accompanied by expression of CHI3L1protein by both
mononuclear cells/macrophages and giant cells of the granuloma
(Johansen et al., 2005). Expression of CHI3L1 in the inflamed
pulmonary environment may affect the function of local lung
macrophages, and thereby favor the production of pro-angiogenic
substances that promote tumor establishment and growth. Our
evidence suggests that expression of CCL2, CXCL2, and MMP-9
by LPS-treated interstitial and alveolar macrophages from normal
mice is enhanced by rmCHI3L1. These results are in agreement
with those of Letuve et al., and Kawada et al., in that CHI3L1
stimulates macrophage production of IL-8 (homolog of mouse
CXCL2),MCP-1 (CCL2) andMMP-9 (Letuve et al., 2008; Kawada
et al., 2012). In addition to its angiogenic function, CCL2 acts
as a chemoattractant molecule that recruits not only tumor cells,
but also leukocytes that provide growth factors for the immigrant
population of tumor cells (Carr et al., 1994; Craig and Loberg,
2006). We have previously shown that T lymphocytes frommam-
mary tumor-bearing mice produce CCL2 and that T cell-derived
CCL2 could also contribute to tumor growth directly via its pro-
angiogenic activity and indirectly by attracting monocytes that
secrete growth-promoting factors (Owen et al., 2005). Decreased
levels of CCL2 therefore may have growth inhibitory activity
on tumor cells. Additionally MMP-9, through its extracellular
remodeling activities, may facilitate the immigration of tumor
cells into the pulmonary environment (Coussens andWerb, 1996;
Werb et al., 1999). Prior studies demonstrating that CHI3L1
promotes both macrophage recruitment and angiogenesis in col-
orectal cancer (Kawada et al., 2012) lend support to the idea that
CHI3L1 expressed by interstitial and alveolar lung macrophages
in the mammary tumor-bearing mice may likewise promote the
migration and growth of metastasizing tumor cells.
At metastatic sites, specific populations of myeloid cells, i.e.,
CD11b+Gr1+ cells, have been found to promote tumor cell
extravasation, seeding and persistent growth (Qian et al., 2009,
2011; Yan et al., 2010). The effect of a primary tumor affect-
ing a distant organ such as the lung was previously investigated
by (Yan et al., 2010), and it was found that CD11b+Gr1+ cells
are increased in number in the “pre-metastatic” lungs of mice
with mammary tumors (Yan et al., 2010). We have previously
shown that splenic CD11b+Gr1 cells express CHI3L1. Since Gr1
marker is a composite epitope between Ly6C and LyG anti-
gens, we assessed the expression on CHI3L1 in CD11b+Ly6C+
vs. CD11b+Ly6G+ populations of cells from total lung and
the lavage. We demonstrate that CD11b+Ly6C+ populations
in the lungs of tumor bearers produce high levels of CHI3L1.
In the study by Yang et al. (2004) CD11b+Gr1 cells in the
pre-metastatic lung down-regulated IFN-γ, contributing to the
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immunosuppressive stage, and we have shown previously that
CHI3L1 downregulates IFN-γ expression by splenic T cells
(Libreros et al., 2012). Additionally, use of CHI3L1 knockoutmice
in an allergic pulmonary model was shown to increase IFN-γ
in comparison to levels in wild type mice with normal CHI3L1
expression (Lee et al., 2009). It may be speculated that CHI3L1
in the pulmonary tissue may have similar effects on local IFN-
γ expression, and thus contribute toward the establishment of
metastases in our mammary tumor bearers. Chitin microparti-
cle suppression of CHI3L1 could counteract this, and our prior
findings of increased IFN-γ levels in chitin microparticle-treated
tumor-bearers is consistent with this hypothesis, as these mice
show decreased mammary tumor growth (Libreros et al., 2012).
Decreased tumor burden is known to affect the success of tumor
cell metastasis to peripheral organs. Binding of chitin to CHI3L1
may neutralize the adverse effects of CHI3L1 on tumor growth
and metastasis both by decreasing angiogenesis and increas-
ing IFN-γ expression. Thus, understanding how molecules like
CHI3L1, expressed in the target organ at “pre-metastatic” stages,
can promote the establishment of cancer cells at these target
sites, may provide insights about how to disrupt these mecha-
nisms therapeutically. Chitin microparticles may represent one
possible method to neutralize the adverse effects of endogenous
CHI3L1 on cancer cell growth, particularly in an inflammatory
tissue environment.
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